P. Deutsch

发表

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

J. Condra, W. Schleif, O. M. Blahy, 1995, Nature.

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

J. Mellors, J. Condra, W. Schleif, 1996, Journal of virology.

A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.

Yudong D. He, R. Stoughton, S. Friend, 2005, Cancer research.

Viral dynamics in human immunodeficiency virus type 1 infection

Martin A. Nowak, Sebastian Bonhoeffer, Xiping Wei, 1995, Nature.

Pharmacokinetics of Montelukast in Asthmatic Patients 6 to 24 Months Old

P. Deutsch, G. Kearns, A. Hartford, 2004, Journal of clinical pharmacology.

A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.

S. Hahn, J. Tepper, P. Deutsch, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Single‐ and Multiple‐Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations

P. Deutsch, K. Lasseter, J. Stone, 2007, Journal of clinical pharmacology.

Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men

A. Sterrett, S. Waldman, P. Deutsch, 2002, Antimicrobial Agents and Chemotherapy.

Potential for Interactions between Caspofungin and Nelfinavir or Rifampin

S. Waldman, P. Deutsch, W. Kraft, 2004, Antimicrobial Agents and Chemotherapy.

Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma

Xin Xu, P. Deutsch, P. Pearson, 2004, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and Safety of Indinavir in Human Immunodeficiency Virus-Infected Pregnant Women

M. Hughes, L. Mofenson, P. Deutsch, 2006, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Ertapenem in Healthy Young Volunteers

S. Waldman, P. Deutsch, H. Greenberg, 2002, Antimicrobial Agents and Chemotherapy.

Single-Dose Pharmacokinetics of Indinavir and the Effect of Food

Eric Woolf, Andrew T. Sterrett, Michael Hesney, 1998, Antimicrobial Agents and Chemotherapy.

Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I.

F. Glorieux, P. Deutsch, F. Rauch, 2005, The Journal of clinical endocrinology and metabolism.

A Phase I/II Study of the Protease Inhibitor Indinavir in Children With HIV Infection

S. Steinberg, R. Nelson, P. Deutsch, 1998, Pediatrics.

Indinavir and Rifabutin Drug Interactions in Healthy Volunteers

S. Waldman, P. Deutsch, W. Kraft, 2004, Journal of clinical pharmacology.

First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist for endothelial protection

P. Deutsch, L. Bergougnan, Anthony J. Muslin, 2020, British journal of clinical pharmacology.

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

C. Lines, P. Deutsch, M. Goldberg, 2003, Clinical pharmacology and therapeutics.

Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer.

S. Doyle-Lindrud, R. DiPaola, J. Nemunaitis, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of MK-0524, a prostaglandin D2 receptor antagonist, on prostaglandin D2-induced nasal airway obstruction in healthy volunteers

P. Deutsch, K. Gottesdiener, K. Mazina, 2007, European Journal of Clinical Pharmacology.

AN IN VIVO POSITRON EMISSION TOMOGRAPHY STUDY OF THE CB1 OCCUPANCY BY AVE1625 USING [C-11]-JHU75528 IN HEALTHY SUBJECTS AND IN PATIENTS WITH SCHIZOPHRENIA.

James Robert Brašić, D. Wong, P. Deutsch, 2010 .

Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.

P. Deutsch, J. Lin, E. Woolf, 1996, Drug metabolism and disposition: the biological fate of chemicals.

Drug interactions between caspofungin and tacrolimus

P. Deutsch, K. Lasseter, J. Stone, 2001 .

Effect of Fluconazole on Indinavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Patients

P. Deutsch, N. Clumeck, S. De Wit, 1998, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Total and Unbound Ertapenem in Healthy Elderly Subjects

P. Deutsch, D. Musson, D. Sciberras, 2004, Antimicrobial Agents and Chemotherapy.

Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.

C. Fuchs, P. Deutsch, Sunil Sharma, 2002, Molecular cancer therapeutics.

Trimethoprim/Sulfamethoxazole Does Not Affect the Steady‐State Disposition of Indinavir

P. Deutsch, J. Seibold, M. Sturgill, 1999, Journal of clinical pharmacology.

Lack of a Pharmacokinetic Interaction between Indinavir and Methadone

P. Deutsch, D. Blazes, J. McCrea, 1999 .

A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer

E. Rosato, J. Tepper, P. Deutsch, 2004, Clinical Cancer Research.

Pharmacokinetics of Ertapenem in Patients With Varying Degrees of Renal Insufficiency and in Patients on Hemodialysis

P. Deutsch, S. Swan, D. Sica, 2006, Journal of clinical pharmacology.

Coadministration of Indinavir and Nelfinavir in Human Immunodeficiency Virus Type 1-Infected Adults: Safety, Pharmacokinetics, and Antiretroviral Activity

D. Havlir, K. Squires, P. Deutsch, 2002, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic Profile and Tolerability of Indinavir-Ritonavir Combinations in Healthy Volunteers

P. Deutsch, A. Saah, M. Nessly, 2001, Antimicrobial Agents and Chemotherapy.

Endothelial‐protective effects of a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist, SAR247799, in type‐2 diabetes rats and a randomized placebo‐controlled patient trial

P. Deutsch, L. Bergougnan, Anthony J. Muslin, 2020, medRxiv.

Losartan Does Not Affect the Pharmacokinetics and Pharmacodynamics of Warfarin

S. Waldman, L. Tomasko, P. Deutsch, 1995, Journal of clinical pharmacology.

A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.

S. Soignet, P. Deutsch, C. Britten, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment.

E. Schadt, S. Monks, A. Sachs, 2005, Genomics.

Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E‐3174

Susan E. Wilson, P. Deutsch, J. McCrea, 1996, Clinical pharmacology and therapeutics.

Tissue Penetration by Ertapenem, a Parenteral Carbapenem Administered Once Daily, in Suction-Induced Skin Blister Fluid in Healthy Young Volunteers

P. Deutsch, M. Guillaume, J. McCrea, 2003, Antimicrobial Agents and Chemotherapy.

Safety and Pharmacokinetics of Higher Doses of Caspofungin in Healthy Adult Participants

P. Deutsch, J. Wagner, J. Stone, 2011, Journal of clinical pharmacology.

Steady‐state pharmacokinetic interaction of modified‐dose indinavir and rifabutin

C. Flexner, P. Deutsch, Hulin Wu, 2003, Clinical pharmacology and therapeutics.

Single-Dose Pharmacokinetics of Indinavir and the Effect of Food

A. Sterrett, S. Waldman, P. Deutsch, 1998, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Intramuscularly Administered Ertapenem

S. Waldman, P. Deutsch, H. Greenberg, 2003, Antimicrobial Agents and Chemotherapy.

Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables.

J. Bilello, J. Condra, P. Deutsch, 1998, The Journal of infectious diseases.

In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds.

J. Condra, W. Schleif, P. Deutsch, 1996, Advances in experimental medicine and biology.

The steady‐state disposition of indinavir is not altered by the concomitant administration of clarithromycin

P. Deutsch, J. Seibold, M. Sturgill, 2000, Clinical pharmacology and therapeutics.